Chemotherapy-induced neutropenia is a very common side effect of cancer chemotherapy, it is treated on the basis of etiology, severity, and duration of the neutropenia. Growing prevalence of different forms of cancer and increasing research and development activities for novel therapeutics are primarily driving the growth of the chemotherapy-induced neutropenia market globally.
The report titled “Chemotherapy Induced Neutropenia Market - Growth, Future Prospects and Competitive Analysis, 2023–2030” offers strategic insights into the overall chemotherapy-induced neutropenia market along with the market size and estimates for the duration 2020 to 2030.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers for understanding the ongoing trends in the global chemotherapy-induced neutropenia market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global chemotherapy-induced neutropenia market. This report concludes with company profiles section that highlights major information about the key players engaged in global chemotherapy-induced neutropenia market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global chemotherapy-induced neutropenia market, offering market size and estimates for the period from 2020 to 2030, keeping in mind the above-mentioned factors.
Chemotherapy-induced neutropenia is a very common side effect of cancer chemotherapy, it is treated on the basis of etiology, severity, and duration of the neutropenia. Growing prevalence of different forms of cancer and increasing research and development activities for novel therapeutics are primarily driving the growth of chemotherapy-induced neutropenia market globally. However, many of these medications are not available to patients in most countries, and even when registered they may not be reimbursed under public health insurance programs which may negatively impacting the growth of chemotherapy-induced neutropenia market. There are different types of treatment available in market for chemotherapy-induced neutropenia which are given on the basis of severity, it includes antibiotic therapy, colony stimulating factor therapy, granulocyte transfusion, splenectomy procedure and other therapy. It is observed that in the base year 2021, colony stimulating factor therapy is major revenue generating segment, due to its preferable use in treatment of chemotherapy induce neutropenia as they have ability to reduce the incidence and severity of neutropenia and febrile neutropenia while improving chemotherapy dose intensity. Regulatory guidelines recommend prophylactic G-CSF treatment for chemotherapy patients with an overall high risk (≥20%) is the prime factor that driving the growth of G-CSF market globally. Currently, Neupogen (filgrastim) and Neulasta (pegfilgrastim) held largest market share approved by the regulatory bodies for treatment of chemotherapy-induced neutropenia.
Chemotherapy induced neutropenia is the dose limiting toxicity of systemic cancer chemotherapy, it is the most serious hematologic toxicity and associated with the risk of life-threatening infections, as well as chemotherapy dose reductions. It is observed that currently, North America is major revenue generating segment due to factors such as increase in prevalence of different forms of cancer, upsurge funding by the government for life-threatening diseases such as cancer, high treatment awareness, higher investment in R&D by key players and research organizations are primarily driving the market growth in North America. On the other hand Asia Pacific is expected to show fastest growth during forecast period due to factors such as rising prevalence of different form of cancer, upsurge funding by the government and private organization for treatment, key manufacturers partnership with local manufacturers and rising treatment awareness would assist market growth in Asia Pacific.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Chemotherapy Induced Neutropenia market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Treatment
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
